Soluble T Cell Immunoglobulin and Mucin Domain-3 (sTIM-3) Predicts Graft-Versus-Host Disease (GVHD) in Iranian Allogeneic Hematopoietic Stem Cell Transplantation

AuthorRonak Nalinien
AuthorElham Roshandelen
AuthorMaria Tavakoli Ardakanien
AuthorMohammad Hossein Kazemien
AuthorHaniyeh Ghaffari-Nazarien
AuthorAbbas Hajifathalien
AuthorMasoud Soleimanien
OrcidRonak Nalini [0000-0002-2070-3681]en
OrcidElham Roshandel [0000-0002-3698-4342]en
OrcidMaria Tavakoli Ardakani [0000-0002-9230-2318]en
OrcidMohammad Hossein Kazemi [0000-0002-2899-9755]en
OrcidHaniyeh Ghaffari-Nazari [0000-0002-4129-6018]en
OrcidAbbas Hajifathali [0000-0002-2711-9277]en
OrcidMasoud Soleimani [0000-0003-1972-7771]en
Issued Date2022-04-30en
AbstractBackground: T cell immunoglobulin and mucin domain-3 (TIM-3) is an immune-checkpoint molecule that is upregulated following allogeneic immune responses and could play an important role in the development and pathogenesis of graft-versus-host disease (GVHD). The soluble form of TIM-3 (sTIM-3) is increased following the upregulation of membranous TIM-3. Objectives: The aim of this study was to evaluate the association between plasma level of sTIM-3 and acute GVHD (aGVHD) incidence in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: Blood samples were collected from 42 allo-HSCT patients and 20 healthy individuals 2 weeks after allo-HSCT. The plasma level of sTIM-3 was measured using enzyme-linked immunosorbent assay (ELISA). The clinical and demographic data of patients were collected from the clinical documents. Data analysis was evaluated using student t-test and one-way ANOVA tests. P-values less than 0.05 were assumed statistically significant. Results: Among 18 (42.8%) patients with aGVHD symptoms, 10 (23.8%) had severe GVHD and 8 (19%) experienced mild GVHD. Plasma sTIM-3 levels at day +14 were significantly higher in patients who developed aGVHD compared to allo-HSCT patients without GVHD and also the healthy control individuals (P-value = 0.015 and < 0.001). Among the aGVHD patients, the sTIM-3 levels in those with severe GVHD were approximately 2.5 times higher than those with mild GVHD (P-value < 0.001). Conclusions: We have identified a high plasma level of sTIM-3 as a valuable biomarker in predicting the development of acute GVHD, especially severe aGVHD in allo-HSCT patients.en
DOIhttps://doi.org/10.5812/ijcm-120888en
KeywordHematopoietic Stem Cell Transplantationen
KeywordGraft-Versus-Host Diseaseen
KeywordTIM-3en
KeywordGVHD Biomarkeren
PublisherBrieflandsen
TitleSoluble T Cell Immunoglobulin and Mucin Domain-3 (sTIM-3) Predicts Graft-Versus-Host Disease (GVHD) in Iranian Allogeneic Hematopoietic Stem Cell Transplantationen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijcm-15-4-120888.pdf
Size:
423.65 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF